SCHEMBL462922

SCHEMBL462922

O=C1C=CC(=O)N1CC1(C(=O)O)CCCCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.46
PTGS1 P23219 5/20 0.36
PTGS2 P35354 5/20 0.36
TBXAS1 P24557 2/20 0.35
KMT2A Q03164 1/20 0.34
MGLL Q99685 5/20 0.33
ALDH1A1 P00352 3/20 0.33
FAAH O00519 3/20 0.33
BLM P54132 2/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
HPGD P15428 2/20 0.33
GMNN O75496 1/20 0.33
THPO P40225 1/20 0.33
PMP22 Q01453 1/20 0.33
CYP1A2 P05177 1/20 0.33
WRN Q14191 1/20 0.33
HIF1A Q16665 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8682479 0.84 MGLL (0.34) CYP2C19PTGS1PTGS2KMT2AMGLL
SCHEMBL4655509 0.84 ALDH1A1 (0.33) CYP2C19PTGS1PTGS2KMT2AMGLL
SCHEMBL30487816 0.83 ALDH1A1 (0.41) CYP2C19KMT2AALDH1A1BLMLMNA
SCHEMBL23854822 0.81 PTGS1 (0.33) CYP2C19PTGS1PTGS2KMT2AMGLL
SCHEMBL20448437 0.80 CYP2C19 (0.47) CYP2C19TBXAS1KMT2AALDH1A1LMNA
Hydrochloric Acid SCHEMBL14765289 0.79 CA12 (0.32) PTGS1PTGS2MGLLFAAHLMNA
SCHEMBL28712712 0.79 CYP2C19 (0.30) CYP2C19
SCHEMBL28600387 0.78 ALDH1A1 (0.38) CYP2C19PTGS1PTGS2ALDH1A1BLM
SCHEMBL7847932 0.77 CA12 (0.49) CYP2C19KMT2AALDH1A1LMNAHPGD
SCHEMBL28613564 0.76 CYP2C19 (0.52) CYP2C19TBXAS1KMT2AALDH1A1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111246873-B Optimized peptides for targeting human nerves and their use in image guided surgery, diagnosis and therapy delivery 加利福尼亚大学董事会 2024-03-01 CN claimed
CN-110062767-B Human antibodies, pharmaceutical compositions and methods 台湾浩鼎生技股份有限公司 2023-07-11 CN claimed
WO-2023113243-A1 MODIFIED OLIGONUCLEOTIDE-DRUG CONJUGATE AND USE THEREOF 인터올리고 주식회사 2023-06-22 WO claimed
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2023-05-04 US claimed
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF SYNTHIS THERAPEUTICS, INC. (US) 2023-03-23 US claimed
CN-115052663-A ALK5 inhibitor conjugates and uses thereof 辛瑟斯治疗股份有限公司 2022-09-13 CN claimed
CN-114929263-A Intercellular adhesion molecule 1(ICAM1) antibody drug conjugates and uses thereof 儿童医学中心公司 2022-08-19 CN claimed
US-20220249680-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2022-08-11 US claimed
EP-3986468-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES Synthis Therapeutics, Inc. (US) 2022-04-27 EP claimed
CN-114269388-A antibody-ALK 5 inhibitor conjugates and uses thereof 辛瑟斯治疗股份有限公司 2022-04-01 CN claimed
EP-2922875-B1 ANTI-CEACAM5 ANTIBODIES AND USES THEREOF SANOFI SA (FR) 2017-03-15 EP claimed
EP-2140263-B1 HAPTEN COMPOUNDS AND COMPOSITIONS AND USES THEREOF UNIV ARKANSAS (US) 2017-01-04 EP claimed
US-8853146-B2 Hapten compounds and compositions and uses thereof THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2014-10-07 US claimed
US-20100143391-A1 HAPTEN COMPOUNDS AND COMPOSITIONS AND USES THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2010-06-10 US claimed
EP-2140263-A1 HAPTEN COMPOUNDS AND COMPOSITIONS AND USES THEREOF Board of Trustees of the University of Arkansas (US) 2010-01-06 EP claimed
WO-2008131216-A1 HAPTEN COMPOUNDS AND COMPOSITIONS AND USES THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2008-10-30 WO claimed
EP-1472351-B1 AMINO ACID SEQUENCES CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER YISSUM RES DEV CO (IL) 2007-06-20 EP claimed
EP-1689846-A2 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES, AND METHODS OF MAKING SAID CONJUGATES Immunogen, Inc. (US) 2006-08-16 EP claimed
WO-2005037992-A2 METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES, AND METHODS OF MAKING SAID CONJUGATES IMMUNOGEN, INC. (US) 2005-04-28 WO claimed
WO-1997040061-A1 ESTROGEN-PURINE BASE, ESTROGEN-MERCAPTURATE ADDUCTS, AND FLUORESCENT PROBES AND MONOCLONAL ANTIBODIES THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 1997-10-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220249680-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 CYP2C19 3531/4885PTGS1 4761/4885PTGS2 4731/4885
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF ALK, ALKBH5, ALKBH3 CYP2C19 3565/4885PTGS1 3620/4885PTGS2 3886/4885
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 CYP2C19 3531/4885PTGS1 4761/4885PTGS2 4731/4885
US-20100143391-A1 HAPTEN COMPOUNDS AND COMPOSITIONS AND USES THEREOF DDT, TAAR5, MLLT1 CYP2C19 572/4885PTGS1 3348/4885PTGS2 3028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.